DexCom (NASDAQ:DXCM) Given Outperform Rating at Leerink Part

Leerink Partnrs restated their outperform rating on shares of DexCom (NASDAQ:DXCM – Free Report) in a research note issued to investors on Monday, PriceTargets.com reports. Leerink Partnrs also issued estimates for DexCom’s Q3 2023 earnings at $0.37 EPS, Q4 2023 earnings at $0.42 EPS, Q1 2024 earnings at $0.30 EPS, Q2 2024 earnings at $0.39 […]

Related Keywords

United States , Zurich , Züsz , Switzerland , Jeremem Sylvain , Leerink Partnrs , Securities Exchange Commission , Bank Julius Baer Co , Dexcom Inc , Clearbridge Investments , Norges Bank , Ltd Zurich , Thrivent Financial For Lutherans , Citigroup , Canaccord Genuity Group , Free Report , Genuity Group , Moderate Buy , Get Free Report , Director Bridgette , Exchange Commission , Julius Baer , Thrivent Financial , Dexcom Share , Dexcom Real Time , Dexcom Daily , Dexcom , Nasdaq Dxcm , Dxcm , Medical , 25213110 , Reiterated Rating ,